摘要
目的观察紫杉醇分别联合奈达铂(NDP)及顺铂(DDP)方案对中晚期卵巢癌治疗的近期疗效及不良反应。方法将42例中晚期卵巢癌患者随机分为治疗组和对照组。治疗组:紫杉醇+奈达铂;对照组:紫杉醇+顺铂。分析两组的近期疗效及不良反应。结果治疗组与对照组的近期有效率分别为54.55%和49.00%,差异无统计学意义(P>0.05);治疗组白细胞减少的发生率(55.00%)和对照组(63.00%),差异无统计学意义(P>0.05);治疗组血小板减少发生率(36.40%)高于对照组(25.00%),但无显著性差异(P>0.05);治疗组胃肠道反应发生率(18.20%)低于对照组(85.00%),差异有统计学意义(P<0.05)。结论奈达铂+紫杉醇为中晚期卵巢癌的有效化疗方案。
Objective To compare the efficacy and safety of paclitaxel combined with nedaplatin （NDP） -based regimen with cisplatin （DDP） -based regimen in treatment of patients with advanced ovarian cancer. Methods A total of 42 patients with advanced ovarian cancer were given with chemotherapy including nedaplatin plus paclitaxel or combination of cisplatin and paclitaxel. The efficacy and side - effects were compared between these two groups. Results The responsive rates of 2 groups were 54.55% and 49.00% respectively in nedaplatin group and cisplatin group, there was no statistical difference between them. The incidence of leueopenia in nedaplatin group was less than that of cisplatin group （ P 〉 0.05 ）. Anemia in cisplatin group was milder than that of nedaplatin group （ P 〉 0.05 ）, and gastrointestinal adverse reactions in nedaplatin group were milder （ P 〈 0.05） than those of other groups. Conclusion The application of nedaplatin and paclitaxel is an effective regimen for treatment of patients with advanced ovarian cancer.
出处
《临床和实验医学杂志》
2013年第22期1830-1832,共3页
Journal of Clinical and Experimental Medicine
关键词
卵巢癌
紫杉醇
顺铂
奈达铂
Ovarian cancer
Paclitaxel
Cisplatin
Nedaplatin
